Results 11 to 20 of about 617 (209)

Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

Vestnik Dermatologii i Venerologii, 2021
Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study.
Luis Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan   +10 more
doaj   +1 more source

Course of uveitis in patients with ankylosing spondylitis during the interleukin 17 inhibitors therapy

Научно-практическая ревматология, 2023
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS).
A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova   +4 more
doaj   +1 more source

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study

Dermatology and Therapy, 2023
Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors.
Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Makiko Mieno, Mamitaro Ohtsuki   +6 more
doaj   +1 more source

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Научно-практическая ревматология, 2020
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis.
T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova   +8 more
doaj   +1 more source

Interleukin-17 inhibitors for the treatment of ankylosing spondylitis

Rheumatology and Immunology Research, 2020
Abstract Tumor necrosis factor inhibitor (TNFi) has been applied in the treatment of ankylosing spondylitis (AS) for many years but still with an unmed need due to inefficacy or intolerance. Current treatment guideline recommended the use of IL-17 inhibitors over a second TNFi in patients with primary nonresponse to the first TNFi.
Huang, Jin-Xian, Zhang, Li-Jun, Wei, James Cheng-Chung   +2 more
openaire   +2 more sources

Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Arthritis Research & Therapy, 2022
Background We explored whether serum cytokines could be used as biomarkers for optimal use of tumor necrosis factor inhibitors (TNF-i) and interleukin (IL)-17 inhibitors (IL-17-i) in patients with psoriatic arthritis (PsA).
Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Shigeru Iwata, Satoshi Kubo, Koshiro Sonomoto, Junpei Anan, Naoaki Ohkubo, Yoshino Inoue, Yoshiya Tanaka   +10 more
doaj   +1 more source

Identification of fused pyrimidines as interleukin 17 secretion inhibitors [PDF]

European Journal of Medicinal Chemistry, 2018
Inhibiting the interleukin 17 pathway is of interest in a number of autoimmune diseases. Herein, 42 fused pyrimidines have been evaluated as interleukin 17 secretion inhibitors using a phenotypic assay with peripheral blood mononuclear cells. 7H-Pyrrolo [2,3-d]pyrimidin-4-amines having aryl groups at C-5 or C-6 were found more active than the ...
Ann Christin Reiersølmoen, Jin Han, Eirik Sundby, Bård Helge Hoff   +3 more
openaire   +3 more sources

Psychiatric aspects of spondyloarthritis

Научно-практическая ревматология, 2021
Spondyloarthritis refers to immune-mediated inflammatory rheumatic diseases characterized by the most pronounced pain, inflammatory activity and disability of patients of working age.
T. A. Lisitsyna, D. Yu. Veltishchev, E. L. Nasonov, A. M. Lila   +3 more
doaj   +1 more source

Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections

Journal of Pharmacological Sciences, 2020
The use of biological drugs in psoriasis is replacing traditional therapies due to their specific mechanism and limited side effects. However, the use of Interleukin 17 inhibitors and the modification of its cytokine pathway could favor the risk of ...
Campione Elena, Cosio Terenzio, Lanna Caterina, Mazzilli Sara, Ventura Alessandra, Dika Emi, Gaziano Roberta, Dattola Annunziata, Candi Eleonora, Bianchi Luca   +9 more
doaj   +1 more source

Psoriasis in areas difficult to treat and biological therapy

Przegląd Dermatologiczny, 2021
Psoriasis often affects specific locations such as the nail apparatus, scalp, hands, feet, and genital areas. It usually coexists with severe plaque psoriasis. However in some cases only these areas may be affected, causing a significant deterioration of
Anna Lis-Święty, Aleksandra Frątczak
doaj   +1 more source